Janus Henderson Group PLC Acquires 449,460 Shares of Eli Lilly and Company (NYSE:LLY)

Janus Henderson Group PLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,484,543 shares of the company's stock after buying an additional 449,460 shares during the quarter. Eli Lilly and Company comprises about 1.8% of Janus Henderson Group PLC's portfolio, making the stock its 9th biggest holding. Janus Henderson Group PLC owned approximately 0.47% of Eli Lilly and Company worth $3,462,267,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. RMR Wealth Builders boosted its stake in Eli Lilly and Company by 2.3% during the fourth quarter. RMR Wealth Builders now owns 4,686 shares of the company's stock worth $3,618,000 after buying an additional 107 shares during the period. Czech National Bank raised its position in Eli Lilly and Company by 6.3% in the 4th quarter. Czech National Bank now owns 170,840 shares of the company's stock valued at $131,888,000 after purchasing an additional 10,143 shares in the last quarter. Aprio Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 10.8% in the 4th quarter. Aprio Wealth Management LLC now owns 2,627 shares of the company's stock valued at $2,028,000 after buying an additional 257 shares during the period. Matrix Trust Co purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at about $164,000. Finally, City Center Advisors LLC raised its holdings in Eli Lilly and Company by 5.4% in the fourth quarter. City Center Advisors LLC now owns 565 shares of the company's stock valued at $436,000 after acquiring an additional 29 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on LLY. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Finally, Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $1,002.80.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $4.89 during midday trading on Tuesday, reaching $750.68. The company had a trading volume of 951,497 shares, compared to its average volume of 3,947,856. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market capitalization of $711.44 billion, a P/E ratio of 64.12, a P/E/G ratio of 1.40 and a beta of 0.48. The firm's fifty day simple moving average is $807.49 and its 200-day simple moving average is $809.36. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same period in the previous year, the firm earned $2.58 EPS. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.